PATENT CLAIM ANALYSIS

Application Number: 16063170
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Claim (Index 6):
The method of  claim 4 , wherein the at least one mutation in the ALK receptor tyrosine kinase polypeptide is at the position corresponding to amino acid residue G1269 of the ALK polypeptide set forth in SEQ ID NO: 4.

Metadata:
- Claim Count in Document: 131.0
- Percentile: 94.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11581865', '15350801', '15683630', '13893141', '13461098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7673802541124692
- 35 USC 102 Novelty (BERT): 0.5374474164644514
- Combined Prediction Score: 0.7443869703476675
- Mean Citation Score: 309.54825199999993
- Max Citation Score: 333.0288
- Similarity Product: 207.04872555913929

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test